The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter 
Professionals >> Visit The Body PROThe Body en Espanol
Ask the Experts About

Choosing Your MedsChoosing Your Meds
Rollover images to visit our other forums!
  • Email Email
  • Glossary Glossary

Nov 30, 2017

Hello Dr. Young,

I would like to know in witch ways RILPIVIRINE is superior/better/less toxic compared to AZT.


Response from Dr. Young

Hello and thanks for posting.

This is an unusual comparison of medications. AZT (zidovudine) is a nucleoside RT inhibitor, while rilpivirine (Edurant, part of Odefsey and Juluca) is a non-nucleoside RT inhibitor. The two classes of drugs are, generally speaking, not interchangable.

Once a key treatment for people living with HIV, AZT is now rarely used- primarily because it's not very well tolerated (common side effects include nausea, vomiting, headaches and muscle aches) and causes significant toxicity (anemia, lipodystrophy).

Rilpivirine is one of the medications in the combination regimen/pills Complera, Odefsey and the new Juluca. It's quite well tolerated and side effects are uncommon, though rash and mood changes have been reported. Rilpivirine has to be taken with food and has a number of significant drug-drug interactions.

I hope that's helpful, BY

Chances of becoming undetectable today (and the HIV care continuum)
SGPT high level

  • Email Email
  • Glossary Glossary



This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint